Therapeutics for the Management of Cytokine Release Syndrome in
COVID-19

Ghosh, Shampa; Durgvanshi, Shantanu; Han, Sung Soo; Bhaskar, Rakesh; Sinha, Jitendra Kumar

doi:10.2174/1568026622666220707114121

Cited by 12 publications

(6 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MPs in the SARS-CoV-2 infected lungs lead to depressed innate proinflammatory immune responses at 2 dpi, with an elevated innate proinflammatory profile identified at 6 dpi. The latter profile showed significant correlation with the ‘cytokine release syndrome’, which is a potentially lethal manifestation of severe COVID-19 ( 117 , 133 ). Thus the influence of MPs might be viewed as moving the inflammatory response away from protective inflammation ( 134 , 135 ) toward pathological inflammation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung

Bishop,

Yan,

Nguyen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionGlobal microplastic (MP) pollution is now well recognized, with humans and animals consuming and inhaling MPs on a daily basis, with a growing body of concern surrounding the potential impacts on human health.MethodsUsing a mouse model of mild COVID-19, we describe herein the effects of azide-free 1 μm polystyrene MP beads, co-delivered into lungs with a SARS-CoV-2 omicron BA.5 inoculum. The effect of MPs on the host response to SARS-CoV-2 infection was analysed using histopathology and RNA-Seq at 2 and 6 days post-infection (dpi).ResultsAlthough infection reduced clearance of MPs from the lung, virus titres and viral RNA levels were not significantly affected by MPs, and overt MP-associated clinical or histopathological changes were not observed. However, RNA-Seq of infected lungs revealed that MP exposure suppressed innate immune responses at 2 dpi and increased pro-inflammatory signatures at 6 dpi. The cytokine profile at 6 dpi showed a significant correlation with the ‘cytokine release syndrome’ signature observed in some COVID-19 patients.DiscussionThe findings are consistent with the recent finding that MPs can inhibit phagocytosis of apoptotic cells via binding of Tim4. They also add to a growing body of literature suggesting that MPs can dysregulate inflammatory processes in specific disease settings.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Transcription factor expressed by multiple cell types in the lung Induced by air pollution (twin study) (132). (see also Supplementary Figure 6)…”

Section: Discussionmentioning

confidence: 99%

Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung

Bishop,

Yan,

Nguyen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Innate proinflammatory immune signatures were generally depressed at 2 dpi, but were elevated at 6 dpi. The profile of cytokine signatures in the lungs at 6 dpi showed significant correlation with the ‘cytokine release syndrome”, which is a potentially lethal manifestation of severe COVID-19 (Budhraja et al, 2022; Ghosh et al, 2023). However, despite this modulation, MP inoculation did not induce overt clinical or histologically-detectable changes in infected mice, suggesting the MP-mediated influences on SARS-CoV-2-mediated disease were clinically mild.…”

Section: Discussionmentioning

confidence: 99%

Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung

Bishop,

Yan,

Nguyen

et al. 2023

Preprint

View full text Add to dashboard Cite

Global microplastic (MP) pollution is now well recognized, with humans and animals consuming and inhaling MPs on a daily basis. Herein we described the effects of azide-free, 1 µm polystyrene MP beads co-delivered into lungs with a SARS-CoV-2 omicron BA.5 inoculum using a mouse model of mild COVID-19. Lung virus titres and viral RNA levels were not significantly affected by MPs, with overt clinical or histopathological changes also not observed. However, RNA-Seq of infected lungs revealed that MP exposure suppressed innate immune responses at 2 days post infection (dpi) and increased pro-inflammatory signatures at 6 dpi. The cytokine profile at 6 dpi showed a significant correlation with the ‘cytokine release syndrome’ signature seen in some severe COVID-19 patients. This study adds to a growing body of literature suggesting that MPs can dysregulate inflammation in specific disease settings.Graphical AbstractHIGHLIGHTSA single inoculation of microplastics dysregulated SARS-CoV-2 lung inflammationAt the peak of SARS-CoV-2 infection microplastics decreased early innate responsesLater post infection microplastics promoted a “cytokine release syndrome” signatureA key mechanism may involve the inhibition of the phagocytosis of infected cellsAzide-free microplastics were used, with no elevated ROS responses identifiedPostulated mechanisms whereby microplastics might decrease the proinflammatory responses 2 days after SARS-CoV-2 infection, yet promote the proinflammatory ‘cytokine release syndrome’ signature at 6 days post infection.

show abstract

“…In the post-COVID-19 era, the integration of nanomedicine into CNS cancer therapy offers a promising path forward. Nanoparticles engineered for precise drug delivery, imaging, and diagnostics are revolutionizing the treatment landscape for CNS cancers [1,6,43]. The pandemic has accelerated the adoption of telemedicine, data sharing, and adaptive strategies, all of which can benefit CNS cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…-Blood-Brain Barrier (BBB): The BBB is a highly selective barrier that limits the passage of therapeutic agents into the brain, making drug delivery to CNS tumors particularly challenging. Traditional chemotherapy drugs often struggle to reach their target in sufficient quantities [6].…”

Section: Challenges In Cns Cancer Therapymentioning

confidence: 99%

<strong></strong>Current Status of Nanomedicine in CNS Cancer Therapeutics in the Post-COVID-19 Era

aventurato

2023

Preprint

View full text Add to dashboard Cite

Central Nervous System (CNS) cancers pose a formidable challenge in the medical world, characterized by aggressive behaviors and limited therapeutic options. The emergence of nanomedicine has offered new hope in CNS cancer treatment. The COVID-19 pandemic has further accelerated the need for innovative therapeutic strategies, emphasizing the significance of nanomedicine in this era. This mini review explores the current status of nanomedicine in CNS cancer therapy, with a particular focus on the post-COVID-19 landscape. We discuss the unique challenges presented by CNS cancers, the potential of nanomedicine in overcoming these challenges, and the recent developments in the field. Additionally, we highlight the lessons learned from the pandemic and how they can be applied to improve CNS cancer therapeutics. We also shed light on the evolving regulatory landscape and the prospects of personalized nanomedicine in CNS cancer treatment. The integration of nanomedicine in CNS cancer therapy is becoming increasingly promising, and its role in the post-COVID-19 era is poised to shape the future of neuro-oncology.

show abstract

Therapeutics for the Management of Cytokine Release Syndrome in COVID-19

Cited by 12 publications

References 97 publications

Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung

Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung

Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung

<strong></strong>Current Status of Nanomedicine in CNS Cancer Therapeutics in the Post-COVID-19 Era

Contact Info

Product

Resources

About